# BioAegis Therapeutics

**Canonical:** https://apis.io/providers/bioaegis-therapeutics/  
**Website:** https://www.bioaegistherapeutics.com/  
**APIs profiled:** 10

BioAegis Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered at the NJ Bioscience Center in North Brunswick, New Jersey. Founded in 2011 around the discovery work of the late Dr. Thomas P. Stossel at Harvard Medical School and Brigham and Women's Hospital, the company develops recombinant human plasma gelsolin (rhu-pGSN) — a protein replacement therapy built on plasma gelsolin (pGSN), an abundant naturally occurring human blood protein that acts as a master regulator of the innate immune response by keeping inflammation localized to the site of injury and boosting the body's ability to clear pathogens. Its lead programme, BTI-203, is a 600-patient, 75-site, 13-country randomized double-blind placebo-controlled Phase 2 study of rhu-pGSN in moderate-to-severe acute respiratory distress syndrome (ARDS), supported by a $20M BARDA DRIVe contract (75A50123C00067); a second Phase 2 programme targets inflammasome-driven decompression sickness under a U.S. Navy Office of Naval Research contract with the University of Maryland School of Medicine. The FDA has granted Fast Track designation for both ARDS and DCS indications. BioAegis holds an exclusive worldwide license from Brigham and Women's Hospital and more than 40 issued patents spanning inflammatory disease, infection, renal failure, neurologic disease and frailty. BioAegis Therapeutics runs no developer program and publishes no product API, developer portal or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.bioaegistherapeutics.com, catalogued here.

## Kin Score — 32.0 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 32.0).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 60.0 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 30.0 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (10)

- **BioAegis Therapeutics Blocks API** — Reusable block patterns and navigation menus. Both registered and reachable, but empty (X-WP-Total 0) — the site is built with Elementor, not the block editor.
- **BioAegis Therapeutics Comments API** — Comment collection. Registered and reachable, but empty (X-WP-Total 0).
- **BioAegis Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **BioAegis Therapeutics Media API** — Media library — 247 attachments at harvest time.
- **BioAegis Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for bioaegistherapeutics.com URLs.
- **BioAegis Therapeutics Pages API** — Corporate pages — 14 published at harvest time (Home, About Us, Our Science, Our Platform, BTI-203 Clinical Trial, FAQs, Publications, News, Careers, Contact Us, Expanded Access...
- **BioAegis Therapeutics Posts API** — Post collection — 153 published items at harvest time, spanning News press releases (94), Publications (34), Events (9), Clinical advisory board profiles (6), Leadership profile...
- **BioAegis Therapeutics Search API** — Cross-content search across published posts and pages.
- **BioAegis Therapeutics Seo API** — Yoast SEO head-tag rendering for a bioaegistherapeutics.com URL — the only anonymously readable operation in the yoast/v1 namespace, and the carrier of the site's schema.org JSO...
- **BioAegis Therapeutics Taxonomy API** — Categories and tags. The hierarchical `category` taxonomy holds 10 terms and carries all classification; the flat `post_tag` taxonomy is registered but empty (0 terms).

## Security (2)

- **Bioaegis Therapeutics Authentication** — 1 scheme
- **Bioaegis Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, biopharmaceuticals, biotechnology, clinical-trials, immunology, inflammation, innate-immunity, gelsolin, protein-therapeutics, ards, critical-care, rare-disease, drug-development, life-sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/bioaegis-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.